Only one of 232 brand-generic patent suit settlements in the US during FY 2016 contained a side deal or commitment not to market an authorized generic.

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Minnesota Attorney General demands Novo Nordisk and Sanofi provide information on their insulin pricing; they are also among several companies facing probes over their contracts with pharmacy benefit managers.